In a 1992 study in rats, the major finding was that intraperitoneal DSIP injection increased the concentration of substance P a neurotransmitter positively correlated with the regulation of anxiety and mood15 in the hypothalamus, suggesting to the researchers that the peptide sharply decreases the classical manifestations of stress.16 Earlier studies in humans, namely a series of five trials published in 1983, came to similar conclusions, with better relaxation and apparently improved tolerance against psychic stress reported by the subjects.17 Its possible that the improved stress and anxiety markers were consequent to DSIP-associated sleep enhancements.18 Substance use recovery A study from 1984 published in European Neurology describes DSIPs potential use as a treatment for alcohol and opiate use disorders
Crohns Disease: Can affect any part of the digestive tract , from mouth to anus, and often extends deeper into the intestinal wall
Decades of research and clinical use confirm minimal risk when used appropriately
Functions as a melanocortin receptor agonist with anti-inflammatory properties studied independently of the full -MSH sequence
Even determining which form of the drug should be used was unclear to regulators, since BPC-157 is not recognized as an official pharmaceutical ingredient in the US
Contains:60 500 mcg capsules of BPC-157, designed to be quickly absorbed by the body